Peter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals of our phase IIa Tourette study, despite tail-end Covid-19 effects at our study sites. We firmly expect to continue to do so. The study remains fully funded. We remain confident of reporting topline results in Q1 2023.”
FINANCIAL HIGHLIGHTS
- Staff costs declined to 0.6 (1.9) MSEK due to the previously communicated reduction in working time for the Asarina team in Q3/2021
- External R&D costs amounted to 2.6 (4.0) MSEK, the majority related to our phase IIa Tourette Syndrome study
- General and administration costs were unchanged at 0.8 (0.8) MSEK
- Our present funding will cover the cost of the study, lasting until summer 2023
- Asarina Pharma AB has now decided to change from quarterly to semi-annual reporting
R&D HIGHLIGHTS
TOURETTE SYNDROME
- The first patient on our Phase IIa Tourette study was enrolled on February 16 at Bispebjerg University Hospital Copenhagen
- Approx. 20% of patients on the study had been randomized by the end of the Quarter
- Bispebjerg University Hospital continues to enroll and treat adult patients with Tourette, who make up the majority of the study. The Danish National Center for Tourette at Herlev University Hospital will focus on children and teenagers, beginning enrolment later in the year
- Last-patient-last-visit is scheduled for January 2023, topline results for Q1 2023
- The study remains fully funded
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/